Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug

Apr 05, 2019 10:45 JST

Source: Eisai

Motion Sickness Solution Now Available in Convenience Stores

TOKYO, Apr 05, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch the mouth freshener Travelmin Support as the first quasi-drug of the Travelmin series which can be purchased even at convenience stores and others in Japan on Monday, April 8.

Travelmin Support is a quasi-drug that contains plant derived daylily extract as its main ingredient to help with motion sickness and discomfort. As a drop-type product, it is easy for children to take, and it has a refreshing cider flavor. Each drop is individually wrapped for convenience, is easy to carry around, and can be taken by both adults and children five of age and older.

After hearing the voices of many consumers who had difficulties because they forgot to purchase motion sickness medicine and were unable to obtain any during their travels, Eisai decided to launch Travelmin Support as a quasi-drug that can be purchased even at convenience stores and others.

The Travelmin series is widely familiar in Japan as a national brand of motion sickness medicines. In addition to Travelmin, which was introduced in 1952, Eisai has launched the drop-type product Travelmin Churop (class 2 pharmaceutical product) which can be taken even after becoming sick, Travelmin R (class 2 pharmaceutical product) which contains ingredients that comparatively cause less sleepiness, and others. With the introduction of Travelmin Support to the Travelmin lineup, Eisai will continue to contribute to people concerned about motion sickness and discomfort when traveling, as well as help consumers enjoy their travels.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Related Press Release

LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

October 14 2025 16:54 JST

Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

October 08 2025 11:03 JST

Eisai Highlights Breadth of Oncology Research at ESMO 2025

October 03 2025 17:01 JST

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

September 29 2025 09:33 JST

LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia

September 24 2025 18:04 JST

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

September 17 2025 17:20 JST

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month

September 12 2025 12:20 JST

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

September 08 2025 16:49 JST

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

September 04 2025 09:56 JST

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

September 03 2025 10:32 JST

More Press release >>

Latest Press Release

FIG, Fujitsu, Acer Medical collaborate to develop health-promoting insurance concept to support preventative care in aging societies
Oct 24, 2025 16:52 JST

SHARP unveils the new "LDK+" EV concept model at Japan Mobility Show 2025
Oct 24, 2025 16:18 JST

Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Training Ship WAKASHIO MARU Built for National Institute of Technology, Toyama College
Oct 24, 2025 00:29 JST

Mazda and Nippon Steel Strengthen Collaboration
Oct 23, 2025 23:57 JST

Immersive Museum "THE MOVEUM YOKOHAMA by TOYOTA GROUP" to Open on December 20, 2025
Oct 23, 2025 23:27 JST

PacificLight Appoints a Consortium of Mitsubishi Power and Jurong Engineering Limited to build 670 MW CCGT Power Plant in Singapore
Oct 23, 2025 23:12 JST

NEC and the Cote d'Ivoire Ministry of Agriculture enhance agricultural efficiency through digital technology
Oct 22, 2025 20:55 JST

Fujitsu and Kawasaki Frontale sign global Sports for Nature Framework in Japan first
Oct 22, 2025 18:16 JST

Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing
Oct 21, 2025 23:00 JST

MHI Thermal Systems to Launch New 2026 Models of the S Series High-Capacity Residential-Use Air-Conditioners for the Japanese Market
Oct 21, 2025 22:10 JST

New Land Cruiser "FJ" Makes World Premiere
Oct 21, 2025 21:29 JST

Sharp Initiates Collaboration with ARAV Corporation for Remote Control Solutions of Construction Machinery Utilizing Satellite Communication
Oct 21, 2025 21:00 JST

Hitachi and OpenAI form strategic partnership centered on global AI data center expansion
Oct 21, 2025 20:06 JST

Indonesia's Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership
Oct 21, 2025 16:45 JST

Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)"
Oct 21, 2025 11:00 JST

MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST

SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST

TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST

MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST

Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST

More Latest Release >>